Clinical Trial Update: A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors [Phase 1]

View source ↗

Summary

First-in-human Phase 1 trial update of the antibody-drug conjugate ADCT-701 in patients with neuroendocrine tumors, neuroendocrine carcinomas, adrenocortical ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma
• Neuroendocrine Carcinoma
• Neuroendocrine Tumor

Drugs mentioned

• ADCT-701

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neuroendocrine Carcinomas, Neuroendocrine Tumors | Phase 1 | Status: RECRUITING